Non-immunological complications following kidney transplantation

F1000Res. 2019 Feb 18:8:F1000 Faculty Rev-194. doi: 10.12688/f1000research.16627.1. eCollection 2019.

Abstract

Kidney transplantation (KT) is the most effective way to decrease the high morbidity and mortality of patients with end-stage renal disease. However, KT does not completely reverse the damage done by years of decreased kidney function and dialysis. Furthermore, new offending agents (in particular, immunosuppression) added in the post-transplant period increase the risk of complications. Cardiovascular (CV) disease, the leading cause of death in KT recipients, warrants pre-transplant screening based on risk factors. Nevertheless, the screening methods currently used have many shortcomings and a perfect screening modality does not exist. Risk factor modification in the pre- and post-transplant periods is of paramount importance to decrease the rate of CV complications post-transplant, either by lifestyle modification (for example, diet, exercise, and smoking cessation) or by pharmacological means (for example, statins, anti-hyperglycemics, and so on). Post-transplantation diabetes mellitus (PTDM) is a major contributor to mortality in this patient population. Although tacrolimus is a major contributor to PTDM development, changes in immunosuppression are limited by the higher risk of rejection with other agents. Immunosuppression has also been implicated in higher risk of malignancy; therefore, proper cancer screening is needed. Cancer immunotherapy is drastically changing the way certain types of cancer are treated in the general population; however, its use post-transplant is limited by the risk of allograft rejection. As expected, higher risk of infections is also encountered in transplant recipients. When caring for KT recipients, special attention is needed in screening methods, preventive measures, and treatment of infection with BK virus and cytomegalovirus. Hepatitis C virus infection is common in transplant candidates and in the deceased donor pool; however, newly developed direct-acting antivirals have been proven safe and effective in the pre- and post-transplant periods. The most important and recent developments on complications following KT are reviewed in this article.

Keywords: kidney transplant; post-transplant complications.

Publication types

  • Review

MeSH terms

  • Antiviral Agents
  • Cardiovascular Diseases / complications*
  • Diabetes Mellitus*
  • Hepatitis C, Chronic / complications*
  • Hepatitis C, Chronic / drug therapy
  • Humans
  • Immunotherapy
  • Kidney Failure, Chronic / surgery
  • Kidney Transplantation*
  • Mortality
  • Neoplasms / complications
  • Neoplasms / prevention & control
  • Postoperative Complications
  • Risk Factors
  • Tacrolimus / adverse effects
  • Tacrolimus / therapeutic use

Substances

  • Antiviral Agents
  • Tacrolimus

Grants and funding

The author(s) declared that no grants were involved in supporting this work.